Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial — but another safety setback mars results
Pfizer’s gene therapy group is back up at bat with a fresh update of data from its Phase Ib study for a gene therapy intended …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
